Pacific Biosciences Of California (PACB) EBITDA (2010 - 2026)

Pacific Biosciences Of California has reported EBITDA for 17 years, with the latest figure at -$42.3 million in Q2 2026.

• On a quarterly basis, EBITDA changed 0.23% year-over-year to -$42.3 million in Q2 2026; TTM through Jun 2026 was -$123.3 million, a 81.76% increase from a year earlier, with the FY2025 full-year figure at -$540.9 million, down 17.45% from the prior year.
• EBITDA was -$42.3 million for Q2 2026 at Pacific Biosciences Of California, down from -$6.2 million in the prior quarter.
• The five-year high for EBITDA was -$6.2 million in Q1 2026, with the low at -$423.8 million in Q1 2025.
• Average EBITDA over 5 years is -$92.8 million, with a median of -$73.8 million recorded in 2022.
• The sharpest annual moves came in 2025 and 2026: EBITDA sank 442.49% in 2025, then jumped 98.55% in 2026.
• Over 5 years, EBITDA stood at -$84.5 million in 2022, then fell by 0.02% to -$84.5 million in 2023, then sank by 77.63% to -$150.2 million in 2024, then soared by 74.4% to -$38.4 million in 2025, then declined by 9.99% to -$42.3 million in 2026.
• The last three EBITDA figures came in at -$42.3 million (Q2 2026), -$6.2 million (Q1 2026), and -$38.4 million (Q4 2025), per Business Quant data.